Nuvation Bio (NUVB) CEO granted 1,995,012 stock options in Form 4

Rhea-AI Filing Summary

Hung David reported acquisition or exercise transactions in this Form 4 filing.

Nuvation Bio Inc. reported that President and CEO David Hung received a grant of stock options covering 1,995,012 shares. These options were awarded at no cash cost to him as a grant, not an open-market purchase.

According to the disclosure, the option vests 25% on the one-year anniversary of 2/27/2026, with the remaining shares vesting monthly over the following 36 months, as long as he continues in service on each vesting date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hung David

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.91	02/27/2026		A		1,995,012		(1)	02/26/2036	Class A Common Stock	1,995,012	$0	1,995,012	D

Explanation of Responses:

1. Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

	/s/ Stephen Dang, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Nuvation Bio (NUVB) CEO David Hung report?

David Hung reported receiving a grant of stock options for 1,995,012 shares of Nuvation Bio Inc. This was a compensation award, not an open-market trade, and increases his potential future ownership if the options vest and are eventually exercised.

How many Nuvation Bio (NUVB) stock options were granted to David Hung?

David Hung was granted stock options covering 1,995,012 shares of Nuvation Bio Inc. This large option award ties part of his compensation to the company’s future share performance, subject to the disclosed vesting schedule and his continued service with the company.

What is the vesting schedule for David Hung’s new Nuvation Bio stock options?

The option vests 25% on the one-year anniversary of 2/27/2026, with the remaining 75% vesting monthly over the following 36 months. Vesting requires David Hung’s continuous service on each vesting date, aligning the award with long-term employment at Nuvation Bio.

Did David Hung buy Nuvation Bio (NUVB) shares on the open market in this Form 4?

No, the Form 4 reports a grant of stock options, not an open-market share purchase. The transaction is coded as an acquisition through grant or award, reflecting equity-based compensation rather than a traditional buy or sell in the market.

What role does David Hung hold at Nuvation Bio (NUVB) in this Form 4?

David Hung is identified as President and Chief Executive Officer of Nuvation Bio Inc. He is also listed as a ten percent owner and director, which is why his equity award transactions must be reported publicly on Form 4 under insider reporting rules.